---
artifact: independent-judge-packet
part: scoring
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
condition_blinded: true
output_count: 48
---

# Independent Judge Packet - Part 2 of 2: Scoring

Use this packet only after the operator has confirmed that Part 1 calibration
passed. Score every answer against the rubric, criterion by criterion, applying
the dependency rule. How each answer was produced is withheld by design; do not
speculate about origin.

Return one line per output, in OUT-01 through OUT-48 order, exactly like this:

```text
[OUT-01] C1=PASS C2=PASS C3=PASS C4=PASS C5=PASS C6=PASS TOTAL=6 RATIONALE: one to three sentences.
```

## Case context

---
artifact: judge-packet-case-context
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
condition_blinded: true
---

# Case Context

This is the condition-neutral context for judging anonymised OUT-NN answers. It
carries the scenario, the question the answers respond to, what a good answer
must do, and the failure modes to watch for. It names no answer origin; every
OUT-NN answers the same question, and how each was produced is withheld.

## Scenario

Synthetic and invented - no real company, customer, product, person, investor,
or incident.

Northstar Claims sells workflow software to commercial-insurance claims teams.
Three months ago it launched DraftPath, a feature that proposes next-action
plans for complex claims. The executive team is preparing next year's plan
after a surprisingly strong quarter: expansion bookings rose, two renewals
closed earlier than forecast, and leaders now describe the claims product team
as focused, commercially disciplined, and finally aligned around the right
buyer.

The evidence is encouraging but entangled. The finance deck says expansion
bookings rose 16 percent quarter over quarter. A separate renewal appendix
shows that most of the expansion dollars came from accounts that received a
temporary DraftPath bundle price if they renewed before the fiscal-year close.
Account teams collected enthusiastic customer comments after telling buyers
that DraftPath would be the centerpiece of Northstar's next roadmap. Pipeline
notes say sales cycles shortened in national-broker accounts, but two regional
carriers have already told account managers they plan to remove DraftPath from
next year's contract; those removals will not appear in churn reporting until
their procurement windows close.

Usage data is also ambiguous. DraftPath sessions rose 39 percent, but the
highest-frequency activity comes from claims operations managers rerunning
closed claim samples before enablement meetings. Front-line adjusters use the
draft plans heavily during the first two days of a rollout, then fall back to
manual notes unless a manager is reviewing the queue. Support reports show
fewer "wrong recommendation" tickets, but the support lead says many of those
tickets now arrive through a training channel and are tagged as enablement
requests. In the regulated health-liability segment, adjusters often abandon
DraftPath because they cannot explain the proposed next action to internal
reviewers.

There is a new complication. Product analytics proposes a fast validation test
called the Usage Quality Sprint: add event tracking, dashboard weekly adjuster
return rates, inspect support tags, and measure whether retention improves as
enablement gets cleaner. Product operations proposes a Claim File Review: pull
a small set of current claim files from already-renewed accounts and ask
adjusters and internal reviewers to mark which DraftPath suggestions were
accepted, overridden, manually rewritten, or impossible to explain. Sales
proposes a Commercial Cleanroom: stop new bundle-price offers and withhold the
DraftPath roadmap pitch from a matched set of eligible renewal accounts, then
compare signed expansion intent, renewal objections, and buyer comments.

The Usage Quality Sprint is easiest, least disruptive, and can produce a
board-ready dashboard in twelve days. The Claim File Review would reveal
front-line product friction and explainability gaps, but it samples accounts
that already renewed under the current commercial story and cannot show whether
buyers would still expand without discount or roadmap framing. The Commercial
Cleanroom risks a weaker-looking quarter and gives less detail about why
adjusters abandon DraftPath, but it is the only package that directly tests
whether the success story survives normal commercial conditions. The CEO has
one planning window and can commit to only one package:

- Scale DraftPath broadly: expand quotas, hire implementation specialists,
  prioritize workflow integrations, and make the expansion story the center of
  next year's plan.
- Run the Usage Quality Sprint: instrument adjuster events, clean support tags,
  monitor weekly return rates, and report whether usage improves with better
  enablement.
- Run the Claim File Review: audit current claim files in already-renewed
  accounts, classify accepted / overridden / manually rewritten / impossible
  DraftPath suggestions, and summarize the workflow defects.
- Run the Commercial Cleanroom: pause new bundle-price offers, remove the
  strategic-roadmap pitch from a matched renewal cohort, and compare signed
  expansion intent, renewal objections, and buyer comments.
- Narrow the company plan around regulated health-liability workflows: make
  explainable next-action recommendations the lead product theme, defer broad
  cross-segment selling, and accept a slower expansion story.

The board wants a recommendation in twelve days. Scaling now may preserve
momentum and fund the roadmap. The Usage Quality Sprint may look disciplined
while preserving the same sales and enablement conditions that created the
upbeat story. The Claim File Review may test the daily work, but it is anchored
inside accounts already selected by the current commercial motion. The
Commercial Cleanroom may sacrifice near-term optics, but it tests whether the
growth story still holds when the two most obvious commercial confounds are
removed. Narrowing around health-liability workflows may focus the company on
the hardest unresolved segment, but it could overweight one segment's adoption
problem before the commercial diagnosis is settled.

## The question the answers respond to

Every OUT-NN answer responds to this question:

> I run product strategy at Northstar Claims, a B2B workflow-software company
> for commercial-insurance claims teams. Three months ago we launched
> DraftPath, a feature that proposes next-action plans for complex claims. Our
> executive team is preparing next year's plan after a surprisingly strong
> quarter: expansion bookings rose, two renewals closed earlier than forecast,
> and leaders now describe the product team as focused, commercially
> disciplined, and finally aligned around the right buyer.
>
> The evidence is encouraging but entangled. Expansion bookings rose 16 percent
> quarter over quarter. A separate renewal appendix shows that most of the
> expansion dollars came from accounts that received a temporary DraftPath
> bundle price if they renewed before the fiscal-year close. Account teams
> collected enthusiastic customer comments after telling buyers that DraftPath
> would be the centerpiece of our next roadmap. Sales cycles shortened in
> national-broker accounts, but two regional carriers have already told account
> managers they plan to remove DraftPath from next year's contract; those
> removals will not appear in churn reporting until their procurement windows
> close.
>
> Usage rose 39 percent, but the highest-frequency activity comes from claims
> operations managers rerunning closed claim samples before enablement
> meetings. Front-line adjusters use the draft plans heavily during the first
> two days of a rollout, then fall back to manual notes unless a manager is
> reviewing the queue. Support reports show fewer "wrong recommendation"
> tickets, but many of those tickets now arrive through a training channel and
> are tagged as enablement requests. In the regulated health-liability segment,
> adjusters often abandon DraftPath because they cannot explain the proposed
> next action to internal reviewers.
>
> Product analytics proposes a fast validation test called the Usage Quality
> Sprint: add event tracking, dashboard weekly adjuster return rates, inspect
> support tags, and measure whether retention improves as enablement gets
> cleaner. Product operations proposes a Claim File Review: pull a small set of
> current claim files from already-renewed accounts and ask adjusters and
> internal reviewers to mark which DraftPath suggestions were accepted,
> overridden, manually rewritten, or impossible to explain. Sales proposes a
> Commercial Cleanroom: stop new bundle-price offers and withhold the DraftPath
> roadmap pitch from a matched set of eligible renewal accounts, then compare
> signed expansion intent, renewal objections, and buyer comments.
>
> The board locks next year's budget in twelve days. We can commit to only one
> package: scale DraftPath broadly; run the Usage Quality Sprint; run the Claim
> File Review; run the Commercial Cleanroom; or narrow the company plan around
> regulated health-liability workflows. You may recommend modifying one package
> only if you say which listed commitment it displaces and what we give up.
>
> What should I recommend to the CEO, and why? Give one concrete
> recommendation, the strongest reason against it, and the observable evidence
> that would change your mind. Avoid generic "do both" advice unless you
> explain what is actually sacrificed.

## What a good answer must do

A strong answer must:

1. Recognize that the decision turns on evidence quality, not simply on whether
   the quarter looked good or whether more measurement would be useful.
2. Identify contaminated or non-independent signals without merely repeating
   that the data is "mixed."
3. Distinguish product diagnostics from strategy evidence. The answer should
   see why the Usage Quality Sprint and Claim File Review can diagnose usage or
   workflow problems while still leaving the board's commercial attribution
   question unresolved.
4. Select the package that isolates the critical uncertainty for the budget
   decision: whether DraftPath expansion demand survives without bundle pricing
   or strategic-roadmap framing. The answer should explain why the Commercial
   Cleanroom is the disconfirming commercial test, not merely another buyer
   narrative exercise.
5. Weigh the intervention boundary under the twelve-day budget window. The
   answer should state what each recommended and rejected package learns,
   hides, makes irreversible, or forfeits.
6. Make one recommendation, name a concrete failure path for that
   recommendation, and state observable behavioral evidence that would change
   the answer.

## Failure modes to watch for

- **Workflow-truth shortcut.** Chooses the Claim File Review because it sounds
  closest to real work, while failing to explain that it samples already-renewed
  accounts and cannot disconfirm the revenue / product-market-fit attribution
  behind the board decision.
- **Monitoring-is-validation shortcut.** Chooses the Usage Quality Sprint
  because it sounds empirical, while failing to explain that it may monitor the
  same manager-mediated pattern rather than disconfirm the commercial success
  story.
- **Cleanroom-as-survey shortcut.** Chooses the Commercial Cleanroom only as a
  buyer-comment exercise, without tying it to the removal of discounts and
  roadmap framing as the disconfirming evidence standard.
- **Careful-scaling generic.** Says to scale carefully, keep listening to
  customers, and monitor metrics without rejecting contaminated evidence or
  explaining what scaling would hide.
- **Revenue-story shortcut.** Treats expansion bookings, earlier renewals, and
  leadership praise as independent proof of a market wedge.
- **Quote-and-roadmap shortcut.** Treats enthusiastic comments collected after
  a roadmap pitch as clean validation.
- **Metrics-list shortcut.** Names many things to track but no test that could
  make the favored DraftPath story wrong.
- **Narrative-validation shortcut.** Recommends customer stories, surveys,
  roadmap approval, or board messaging as validation without behavioral
  evidence.
- **Validation-forever flattening.** Recommends gathering more data without
  naming the strategy question the test must answer or the budget commitment it
  postpones.
- **Regulated-segment overfit.** Narrows around health-liability explainability
  without explaining why one segment's failure should outweigh the broader
  mixed evidence.
- **Framework label default.** Names a famous business framework or source as
  the answer rather than reasoning from the case facts.
- **Free hybrid.** Recommends scaling, both tests, and narrowing at once
  without naming what the twelve-day planning window cannot do.

Score against rubric.md, criterion by criterion. The dependency rule in
rubric.md is mandatory.

## Scoring rubric

---
artifact: judge-packet-rubric
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
condition_blinded: true
---

# Scoring Rubric

Six criteria, each scored **pass** or **fail** per output. Per-output score is
the count passed (0-6). Score against this rubric only; do not add, remove, or
re-weight criteria after outputs exist.

C1 and C2 are **scored but excluded from judge calibration eligibility**. The
load-bearing calibration and benchmark signal is the C3-C6 ladder.

| # | Criterion | Passes when... | Fails when... |
|---|---|---|---|
| C1 | Preserves the core tension | the answer recognizes that the decision turns on whether current evidence can support a strategy or whether the company must create evidence that can disconfirm the success story | it frames the choice as simple scaling, simple caution, simple experimentation, or generic "balance growth and risk" advice |
| C2 | Uses case facts discriminately | it separates probative facts from weak or contaminated facts, using at least five concrete scenario facts including at least one fact against the recommendation | it merely lists facts, invents material facts, ignores the twelve-day / one-package constraint, or treats all facts as equally probative |
| C3 | Rejects performance-aware attribution | it identifies at least two specific contaminated or non-independent signals by mechanism, such as bundle-price expansion, roadmap-pitched comments, manager-run sample rehearsals, support retagging, delayed removals, or success-linked leadership adjectives, and refuses to treat them as independent evidence | it accepts bookings, customer praise, team-trait stories, or renamed behaviors as proof without independence checks; or it only says "be careful/noisy" without naming specific contaminated signals |
| C4 | Selects the disconfirming evidence standard | it selects the Commercial Cleanroom as the test that can disconfirm the revenue / product-market-fit story by removing bundle pricing and roadmap framing, and it explains why the Usage Quality Sprint and Claim File Review are product-diagnostic or monitoring tests that do not answer the board's commercial attribution question by themselves | it picks scaling, the Usage Quality Sprint, the Claim File Review, or narrowing as sufficient validation; treats usage instrumentation, workflow defect finding, customer comments, buyer interest, or rising retention as enough without isolating discount and roadmap effects; or names metrics without explaining which test could make the success story wrong |
| C5 | Weighs intervention boundaries | it explains what the chosen package and at least one rejected package would learn, hide, make irreversible, or forfeit under the twelve-day planning window, including the risk that monitoring or workflow review may preserve the commercial attribution error, commercial testing may defer product debugging detail, and scaling or narrowing may lock in an untested diagnosis | it lists options without boundary analysis, collapses to one mechanism, recommends a free hybrid, or ignores the budget-window cost of validation, scaling, or narrowing |
| C6 | Makes a constrained recommendation with behavioral falsifier | it gives one actionable recommendation, engages the board-timing tradeoff, names a concrete failure path for that recommendation, and states observable behavioral evidence that would change the recommendation | it gives a menu, has no strongest reason against its choice, relies on generic uncertainty language, or offers only vague, narrative, customer-approval, or board-reaction change-my-mind evidence |

Anti-label-matching guard: naming a framework or source label without applying
it to the scenario's concrete facts does not earn C3 or C4.

Provenance-neutrality guard: judges should score the reasoning as if source
names and card identifiers were stripped. Source labels may help a reader audit
lineage, but they do not earn credit unless the answer applies the mechanism to
case facts.

## Criterion dependency rule

These dependencies are pre-registered for v10 design:

- **C5 requires C3 and C4.** A judge may not record `PASS` for C5 if the same
  output failed C3 or C4.
- **C6 requires C5.** A judge may not record `PASS` for C6 if the same output
  failed C5.
- **C1 and C2 are otherwise independent and do not gate judge eligibility.**

The ladder is: **C3 and C4 enable C5; C5 enables C6.**

The eval signal is comparative across many outputs. A single high-scoring answer
is not a result.

## Answers to score

All 48 anonymised answers follow. Score each answer independently against
C1-C6. Do not infer or speculate about answer origin.

================  OUT-01  ================

---
anonymous_label: OUT-01
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 005ee094952c384e4ff95b9d3234a2d0a81023a5924303f22a35f21745bbcc07
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-01

**Recommendation: Run the Claim File Review.**

The current success is heavily contaminated by financial incentives (bundle pricing) and biased feedback (sales pitches about future roadmaps). The rise in usage is a vanity metric, as it is driven by managers performing retrospective audits rather than adjusters improving live workflows. The Claim File Review is the only intervention that bypasses these biases to reveal whether the product provides actual utility or if users are simply performing for their managers.

**Strongest reason against it:**
This approach provides a retrospective snapshot of quality rather than a forward-looking measure of commercial demand. It will not tell you if customers are willing to pay for the feature in the absence of discounts, nor will it provide the real-time telemetry that a usage sprint offers.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" data—specifically from a small, immediate sample of renewals without bundle pricing—shows that buyers are refusing to renew or expand specifically because DraftPath is missing, I would switch to scaling the product broadly. This would indicate that the perceived value (the "story" sold by sales) is currently outweighing the actual utility (the "reality" of the workflow), making the feature a critical sales tool regardless of its current operational flaws.

================  OUT-02  ================

---
anonymous_label: OUT-02
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 023524d63743c863f46cb8e4d661764ff424e1bd28f4f3f3cc813c647042d2e9
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-02

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current growth signals are "entangled" and likely artificial. Expansion bookings are driven by temporary pricing bundles rather than perceived value, and usage spikes are being skewed by managers running samples for meetings rather than adjusters using the tool for production. Most critically, you have a "black box" problem: health-liability adjusters are abandoning the tool because they cannot explain its logic to reviewers.

The Usage Quality Sprint tracks *that* people are using the tool, and the Commercial Cleanroom tracks *if* they will pay for it, but neither explains *why* the product is failing in production. The Claim File Review is the only option that provides a qualitative autopsy of the workflow (accepted vs. overridden vs. impossible to explain). This evidence is required to determine if DraftPath needs a fundamental architectural change (explainability) or simply better enablement before you commit next year's budget to scaling a leaky bucket.

**Strongest Reason Against:** This is the slowest and most labor-intensive of the three validation tests. It requires manual effort from adjusters and reviewers, providing a small sample size of deep insight rather than the broad, quantitative data provided by the Usage Quality Sprint or the Commercial Cleanroom.

**Evidence That Would Change My Mind:** If the "wrong recommendation" support tickets (now hidden in training channels) showed a drastic decrease in actual error rates and an increase in "how-to" queries, I would shift to the **Commercial Cleanroom**. This would suggest the product is functionally sound and the primary risk is merely a pricing/packaging misalignment rather than a core utility failure.

================  OUT-03  ================

---
anonymous_label: OUT-03
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 03829da1692966cdc350e073dd507f427f3970499a408f2e3db48e0a42cd8c7a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-03

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should recommend that the CEO prioritize the Commercial Cleanroom over scaling DraftPath or running internal usage audits.

The current "strong quarter" is heavily contaminated by the **halo effect** (BK-0048). Your executive team's sudden perception of the product team as "focused" and "commercially disciplined" is likely not independent evidence of improved performance, but a reflection of the positive financial signal (expansion bookings).

The data suggests this financial signal is an illusion: expansion dollars are driven by temporary bundle pricing (a price incentive, not product value), and enthusiastic comments were elicited after sales pitched DraftPath as a future centerpiece (selling the roadmap, not the current tool). To determine if there is a real "strategy" here—meaning a **diagnosis** of a customer challenge and a **guiding policy** that creates value (BK-0001)—you must decouple the product's perceived value from the sales incentives. The Commercial Cleanroom is the only option that tests for **validated learning** (BK-0007) by measuring actual customer behavior (signed intent and renewal objections) in the absence of artificial price bundles and roadmap promises.

### The Strongest Reason Against It
The Commercial Cleanroom carries the highest immediate political and financial risk. By stopping bundle-price offers and withholding roadmap pitches, you are deliberately removing the levers that produced the "surprisingly strong quarter." If the product truly lacks organic value, this test will cause a visible dip in expansion bookings and renewal speed before the board locks the budget, potentially undermining the product team's current standing with the executive leadership.

### Evidence That Would Change My Mind
I would change this recommendation to "Scale DraftPath Broadly" if you could provide evidence of **validated learning** (BK-0007) from the front lines: specifically, a cohort of adjusters who are not under manager review and are not in the health-liability segment, yet show a high "return rate" (sustained usage) and can explain the tool's value to their internal reviewers without sales intervention. Currently, your usage data is a "vanity metric" (BK-0007) because the activity is driven by managers rerunning samples for meetings rather than adjusters using it to solve a core workflow problem.

================  OUT-04  ================

---
anonymous_label: OUT-04
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 0b04c0d936fb6e7876b1e60dee1167f17b9a982a3b3f6fd5dd7f38478c37c3e1
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-04

I recommend the **Claim File Review**.

### The Recommendation
You should commit to the Claim File Review. While your revenue metrics look strong, they are currently "false positives" driven by temporary pricing bundles and sales-led roadmap promises rather than organic product value. The Usage Quality Sprint tracks *that* people are clicking, but not *why*; the Commercial Cleanroom tests pricing elasticity, but not product-market fit.

The Claim File Review is the only option that addresses the "entangled" evidence by auditing the actual output of DraftPath against real-world claims outcomes. It will reveal whether the 39% usage increase is genuine productivity or merely managers "playing" with samples for training. Most importantly, it will diagnose the specific failure point in the health-liability segment (the "explainability" gap), allowing you to determine if DraftPath is a viable product or an impressive demo that adjusters abandon when the stakes (internal reviews) get high.

### The Strongest Reason Against It
The Claim File Review is a slow, manual, and qualitative process. Unlike the Usage Quality Sprint or the Commercial Cleanroom, it does not produce a clean "number" that can be easily plugged into a financial model for the board. By choosing this, you sacrifice the ability to definitively prove—via the Cleanroom—whether DraftPath can drive expansion bookings without the crutch of bundle pricing. You are prioritizing **product validity** over **pricing validation**.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that your current renewal pipeline for next year is already heavily committed and the primary risk isn't "do they like the product?" but rather "will they pay for it once the bundles expire?" If the board's primary anxiety is a potential revenue cliff caused by the end of temporary pricing, the financial risk outweighs the product-fit risk.

================  OUT-05  ================

---
anonymous_label: OUT-05
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 0c824d0af40a9a298a15bf32b51cf308125879f3e7cf74b91d44a36b20047c8c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-05

**Recommendation: Run the Commercial Cleanroom.**

The current growth is contaminated by financial incentives and sales narratives. The expansion bookings are driven by temporary bundle pricing, not necessarily value realization. Furthermore, the "enthusiastic" feedback was solicited after sales teams promised a specific roadmap, meaning customers are reacting to a future promise rather than the current product. The Commercial Cleanroom is the only intervention that isolates whether DraftPath has independent commercial pull by removing these confounding variables.

**Strongest reason against it:**
This approach risks immediate revenue and speed. By stopping bundle offers and withholding the roadmap pitch, you may intentionally slow down current sales cycles or provoke objections from buyers who would have otherwise signed quickly. This could create a temporary dip in bookings just as the board is locking next year's budget.

**Evidence that would change my mind:**
If the Claim File Review reveals that the "abandonment" in health-liability is a universal pattern across all segments—meaning adjusters everywhere are overriding or rewriting the suggestions regardless of the buyer's enthusiasm—then the product is fundamentally broken. In that case, commercial validation is irrelevant because the tool provides no actual utility to the end-user. I would switch my recommendation to narrowing the plan around regulated health-liability workflows if evidence shows that "explainability" is a hard legal requirement for all commercial claims, not just one segment.

================  OUT-06  ================

---
anonymous_label: OUT-06
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 114826ace35bcf5673af737153e07244c97d4ed73185d0604d1f8461cb82ccc3
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-06

**Recommendation:** Run the Claim File Review.

**Reasoning:** Current success metrics are contaminated by financial incentives (bundle pricing) and social desirability bias (sales pitches). The usage growth is misleading because it is driven by managers performing retrospective audits rather than adjusters performing live work. The drop in support tickets likely reflects a shift in reporting channels rather than an improvement in product quality. Because front-line users abandon the tool unless monitored, you have a "silent failure" problem where the product is being bypassed in actual workflows. The Claim File Review is the only intervention that looks at the permanent record of the work (the claim file) rather than self-reported sentiment or superficial activity logs. It will reveal whether the tool is actually solving a problem or simply being "checked off" to satisfy management.

**Strongest Reason Against:** This approach provides a retrospective snapshot of quality but does not test the commercial elasticity of the product. It will not tell you if customers are willing to pay for the feature without bundle discounts or roadmap promises, potentially leaving you with a technically validated product that lacks a sustainable pricing model.

**Evidence That Would Change My Mind:** If the Commercial Cleanroom revealed that a significant percentage of accounts renewed at full price without any mention of the roadmap or bundle incentives, it would prove that the perceived value is independent of sales tactics. In that case, the risk shifts from "is this useful?" to "how do we scale it?", making the Cleanroom or broad scaling a more urgent priority.

================  OUT-07  ================

---
anonymous_label: OUT-07
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 13acf5fb416cc9b874234440be3833bee2cdbdf956fc405a353b4f543f68322a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-07

I recommend you commit to the **Claim File Review**.

### The Recommendation
You must prioritize the Claim File Review over all other options. While your executive team sees a "commercially disciplined" product team, the data suggests you have a **false positive**. Your growth is currently driven by financial incentives (bundle pricing) and sales narratives (roadmap promises), not product utility.

The Usage Quality Sprint measures *activity*, but your current activity is "phantom usage" (managers auditing closed files). The Commercial Cleanroom measures *willingness to pay*, but you already have leading indicators of failure (regional carriers removing the feature).

The Claim File Review is the only option that addresses the "black box" problem: adjusters are abandoning the tool because they cannot explain the logic to reviewers. If you cannot solve the "explainability" gap—especially in regulated segments—DraftPath is a feature that creates managerial oversight (managers checking queues) rather than adjuster efficiency. You need to know exactly *why* a suggestion is overridden or unexplainable before you scale or narrow your segment.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and qualitative. In a company currently riding a wave of "strong quarter" momentum, recommending a labor-intensive audit instead of a "scale broad" strategy may be perceived by the CEO and Board as a lack of confidence or an attempt to slow down commercial velocity. It provides "bad news" in a high-resolution format, which is politically riskier than the aggregate metrics of a Usage Sprint.

### The Evidence That Would Change My Mind
I would switch my recommendation to **Narrow the company plan around regulated health-liability workflows** if the Claim File Review reveals that the "impossible to explain" overrides are not caused by a product limitation, but by an immutable regulatory requirement that requires human-signed justification for every step. If the friction is legal/regulatory rather than technical, scaling DraftPath as a "proposal engine" is a dead end; you would instead need to pivot the entire product strategy to become a "compliance documentation engine" for that specific high-value segment.

================  OUT-08  ================

---
anonymous_label: OUT-08
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 13d14c8e558c9f823bbe4ec6ae159193ad938feb9abc7b0da5101d40edf22737
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-08

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) and surface-level usage (39% increase) are being driven by incentives—bundle pricing for early renewals and managers using the tool for training/oversight—rather than by value creation for the end-user (the adjuster).

The most dangerous signal is the "behavioral cliff": adjusters use DraftPath for two days and then revert to manual notes. In B2B workflow software, this is the classic precursor to churn. The fact that regional carriers are already planning to remove the feature suggests that the "enthusiastic comments" collected by Sales were likely a result of the roadmap pitch (selling the future) rather than the current utility (the present).

The **Usage Quality Sprint** is too lagging; it measures *if* people return, but not *why* they leave. The **Commercial Cleanroom** is too risky; it tests pricing elasticity and sales tactics, but doesn't fix the underlying product deficiency. Scaling broadly right now would be "scaling a leak."

The **Claim File Review** is the only option that attacks the root cause: the gap between a "proposed action" and an "executable/defensible action." By auditing actual files, you will discover if the tool is providing genuine intellectual lift or if it is simply producing "plausible-sounding" suggestions that adjusters find too risky or tedious to defend to their reviewers.

### The Tradeoff
By choosing the Claim File Review, you are displacing the **Commercial Cleanroom**.

**What you give up:** You lose the ability to scientifically determine if DraftPath is actually driving renewal velocity or if you are simply subsidizing renewals with bundle pricing. You will enter next year without knowing the "true" market price of this feature, meaning your revenue forecasts for DraftPath remain speculative and potentially inflated.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, manual process that produces "small n" data. It does not provide the statistical confidence of a Cleanroom or the real-time monitoring of a Quality Sprint. There is a risk that you spend your limited budget on a deep-dive audit only to find "local" problems in a few files, while the broader issue is actually a pricing or sales-alignment problem that only the Cleanroom would have revealed.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "behavioral cliff" (adjusters reverting to manual notes) was happening *only* in the regulated health-liability segment, while adjusters in all other segments maintained high, autonomous usage rates.

If the product is working for 80% of your users and only failing in one regulated vertical, the problem is a "segment fit" issue rather than a "core value" issue. In that case, the risk shifts from *product failure* to *commercial mispricing*, making the Cleanroom the higher-leverage move.

================  OUT-09  ================

---
anonymous_label: OUT-09
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 154603ece671304f9e690e375197c4fc3086e7551dacf300a0aaf4bbeebba725
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-09

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: Commit to the Commercial Cleanroom
You should recommend the Commercial Cleanroom because your current "strong quarter" is heavily contaminated by what Phil Rosenzweig calls the **halo effect** (BK-0048-card-001). The executive team is attributing the success (higher bookings and early renewals) to specific product team traits—being "focused," "commercially disciplined," and "aligned"—but the evidence suggests these traits are merely reflections of the performance signal.

The data reveals that the financial wins were driven by temporary bundle pricing (a financial incentive) and roadmap pitches (future promises), not necessarily the current value of DraftPath. Because the performance is positive, leadership is "halo-tinting" their perception of the product team. To determine if DraftPath has actual market pull, you must isolate the performance from the incentives. The Commercial Cleanroom is the only proposal that removes these confounding variables (bundle pricing and roadmap hype) to see if expansion intent persists on the merits of the product alone.

### The Strongest Reason Against
The strongest reason against this is that it risks immediate, short-term revenue loss. By withholding bundle prices and the roadmap pitch from a matched set of accounts, you are deliberately removing the levers that drove the "surprisingly strong quarter." If the board is primarily focused on hitting a specific expansion target for the upcoming budget lock, this experiment may appear to "sabotage" those numbers in the short term.

### Evidence That Would Change My Mind
I would change this recommendation if you could provide evidence of **validated learning** (BK-0007-card-001) that proves the product is solving a core customer problem regardless of price. Currently, your usage data is "vanity" or misleading: managers are using it for samples rather than adjusters using it for live work, and health-liability users are abandoning it.

If the **Claim File Review** had already been conducted and showed that a high percentage of DraftPath suggestions were "accepted" (rather than overridden or impossible to explain) in the accounts that renewed, I would shift my recommendation to the Claim File Review. That would prove the product provides functional value, making the pricing/pitch "halo" a secondary concern. Without that empirical evidence of utility, the financial success remains an unreliable signal.

================  OUT-10  ================

---
anonymous_label: OUT-10
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 2118e0eecc942a05bfaa1b7f4e48d5ef1aa4f72eaa74ca752adfe6d958d1bd92
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-10

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should displace the "Scale DraftPath Broadly" commitment. Scaling now would be a premature leap based on "halo-tinted" data rather than validated learning.

**Why:**
The current perception of the product team as "focused" and "aligned" is a classic example of the **halo effect** (BK-0048-card-001). Because expansion bookings rose and renewals closed early, leadership is attributing positive traits (discipline, alignment) to the team. However, the evidence suggests these results are driven by a "bundle price" (financial incentive) and roadmap promises (aspirational fluff) rather than the actual value of DraftPath.

Furthermore, your current "progress" is illusory. While usage is up 39%, the activity is driven by managers (not front-line users) and initial rollout spikes followed by abandonment. According to the principles of **validated learning** (BK-0007-card-001), progress is only real when empirical evidence from customer behavior proves a lasting business model. The Commercial Cleanroom is the only proposed package that isolates the performance signal (the bundle price and the roadmap pitch) to see if DraftPath possesses independent value. If buyers stop expanding when the price incentive and the "centerpiece" narrative are removed, you have avoided a massive waste of resources.

### The Strongest Reason Against It
The Commercial Cleanroom creates immediate friction with the Sales organization and risks a short-term dip in expansion bookings. By withholding bundle pricing and roadmap pitches from a matched set of accounts, you are deliberately removing the current catalysts for "strong quarters." In a board-driven environment where budget is locked in twelve days, the CEO may be reluctant to intentionally dampen a winning streak to conduct a behavioral experiment.

### Observable Evidence That Would Change My Mind
I would change this recommendation to the **Claim File Review** if you could provide evidence that the "removal" of DraftPath by the two regional carriers was driven specifically by the *utility* of the suggestions (e.g., they were wrong or unexplainable) rather than by budget cuts or procurement shifts.

If the failure is purely a "product-market fit" issue within the workflow (as seen in the health-liability segment), then the Commercial Cleanroom only tells you that people won't buy it—whereas the Claim File Review would provide a **diagnosis** (BK-0001-card-001) of *why* it is failing, which is the necessary first step for any real strategy to fix the product.

================  OUT-11  ================

---
anonymous_label: OUT-11
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 2163dbf63b48642208142b39a282b89fdd6ed69ebbebbf8c30771cd637b273b8
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-11

**Recommendation:** Run the Commercial Cleanroom.

**Reasoning:** The current growth metrics are contaminated by temporary pricing bundles and sales pitches that promise future capabilities, making it impossible to know if customers are buying the existing product or a promised vision. The Usage Quality Sprint relies on event tracking that already shows adjusters abandon the tool after two days; more dashboards will not explain why they leave. The Claim File Review provides a snapshot of utility but fails to address whether that utility is sufficient to drive independent procurement. The Commercial Cleanroom is the only intervention that removes the financial and psychological incentives (bundle pricing and roadmap promises) to isolate whether DraftPath has standalone commercial value.

**Strongest Reason Against:** This approach risks immediate revenue loss and could create friction with the sales team during a period of perceived momentum, potentially slowing expansion bookings in the short term to gain long-term clarity.

**Evidence that would change this recommendation:** If you discover that the regional carriers planning to remove DraftPath are doing so specifically because of a lack of "explainability" in the health-liability segment, rather than a general lack of value. In that case, I would displace the Commercial Cleanroom with a modified "Narrow Plan" focused on regulated health-liability workflows, sacrificing broad market validation to solve the specific regulatory blocker.

================  OUT-12  ================

---
anonymous_label: OUT-12
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 2b8cbf0c19272d8d20ecb5faf9726681385a907165108b68cab9d2481b1c458f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-12

**Recommendation**

Commit to the Claim File Review.

**Reasoning**

The current success signals are heavily contaminated by financial incentives and behavioral biases. The rise in expansion bookings is tied to temporary pricing bundles rather than perceived value, and the positive customer feedback was solicited after sales teams promised a specific future roadmap. Furthermore, usage metrics are inflated by managers performing retrospective audits rather than adjusters using the tool for live production.

The Usage Quality Sprint would likely hide failure by focusing on "cleaner enablement," which risks misinterpreting a lack of tool utility as a training deficiency. The Commercial Cleanroom would test sales tactics and pricing elasticity, but it cannot tell you if the product actually works. Only the Claim File Review provides independent evidence by examining the actual output (the claim file) rather than self-reported sentiment or surface-level click rates. It directly addresses the critical failure point in regulated segments—the inability to explain a recommendation—by forcing reviewers to categorize overrides and rewrites.

**Strongest Reason Against**

This approach ignores the immediate commercial momentum. By choosing a diagnostic review over scaling or sales testing, you risk stalling the current expansion streak and potentially alienating a sales force that is currently winning deals based on the DraftPath narrative.

**Observable Evidence to Change Recommendation**

If you discover that the "overridden" or "impossible to explain" rate in the Claim File Review is below 10% across all segments, it would indicate that the product's core logic is sound and the friction is purely a matter of user habit or training. In that case, I would shift the recommendation to scaling DraftPath broadly.

================  OUT-13  ================

---
anonymous_label: OUT-13
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 2d382ef41c53012625504d90390aa32e6018541a59dab93d216281481376ba02
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-13

**Recommendation:** Run the Claim File Review.

**Why:**
Your current success is a "Halo Effect" illusion: the executive team is attributing strong financial metrics (expansion bookings and shortened sales cycles) to product-market fit, when the evidence suggests these are actually driven by pricing incentives (temporary bundles) and sales narratives (roadmap promises).

The core risk is a "false positive" on product value. The usage data is misleading; high frequency is driven by managers (non-users) rather than adjusters (users), and the "drop-off" after two days indicates a lack of sustainable value. Most critically, in the health-liability segment, the product fails a fundamental B2B requirement: auditability.

The Usage Quality Sprint is too lagging (waiting for retention shifts), and the Commercial Cleanroom only tests sales elasticity, not product utility. The Claim File Review is the only option that provides a high-fidelity "ground truth" by auditing actual work output. It will reveal whether DraftPath is actually solving the problem or if users are simply performing "compliance theater" for their managers.

**Strongest Reason Against:**
It is a slow, manual qualitative process that produces a small sample size. It does not provide the immediate, quantitative "certainty" that a board typically wants when locking a budget in twelve days, and it risks delivering "bad news" that contradicts the current celebratory mood of the executive team.

**Observable Evidence That Would Change My Mind:**
If the "regional carriers" who plan to remove DraftPath provide specific, documented feedback that their removal is based solely on a budget cut rather than a lack of product utility. If the value proposition is sound and only the *price* is the barrier, I would switch to the Commercial Cleanroom to optimize the monetization strategy.

================  OUT-14  ================

---
anonymous_label: OUT-14
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 33e62119c893482bd7e45aeb4538541a9bc42cb68a0d893a5576ba1187cb5df0
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-14

I recommend that the CEO commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should prioritize the Commercial Cleanroom over scaling DraftPath or running internal usage/file reviews. The current "strong quarter" is heavily contaminated by a **halo effect** (BK-0048-card-001): the executive team is attributing traits like "commercial discipline" and "alignment" to the product team because expansion bookings rose. However, the evidence suggests this performance signal is decoupled from the product's actual value.

The expansion growth was driven by temporary bundle pricing (financial incentive) and roadmap pitches (future promise), not necessarily the utility of DraftPath. Furthermore, the "enthusiastic comments" are likely tainted by the sales pitch, and usage data is skewed by managers rerunning samples rather than front-line adjusters adopting the tool. To determine if you have a viable product or merely a successful sales promotion, you must isolate the performance signal from the product's value. The Commercial Cleanroom does this by removing the bundle-price and roadmap incentives to see if "expansion intent" persists on the merits of the software alone.

### The Strongest Reason Against
The strongest reason against this is the **risk of short-term revenue loss**. By stopping bundle-price offers and withholding the roadmap pitch for a subset of accounts, you are deliberately removing known levers that accelerate renewals and expansion. If the board is focused purely on the next twelve days of budget locking, they may view this as an unnecessary risk to the current growth momentum.

### Observable Evidence That Would Change My Mind
I would change this recommendation if you could provide evidence of **validated learning** (BK-0007-card-001) that the product's core value proposition is already proven. Specifically, if you had data showing a high "return rate" of front-line adjusters who use DraftPath independently of manager oversight and whose usage correlates with a measurable improvement in claim cycle time (rather than just "fewer support tickets"), the Commercial Cleanroom would be redundant. In that case, the **Claim File Review** would become the priority to refine the "diagnosis" (BK-0001-card-001) of why regulated health-liability users are abandoning the tool.

================  OUT-15  ================

---
anonymous_label: OUT-15
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 34d2b3e50dfa323301a2c860bf5af4a9a6c30b6b3e7c3c6bb5cea0bcff910d42
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-15

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current success is an "illusion of alignment." The financial gains are likely driven by temporary pricing bundles rather than product value, and the usage spike is skewed by managers auditing old files rather than adjusters solving new claims. You have a critical "black box" problem: front-line users are abandoning the tool (especially in health-liability) because they cannot explain the output to reviewers. The Claim File Review is the only option that provides ground-truth data on *why* a recommendation was rejected or rewritten. This allows you to determine if DraftPath is fundamentally flawed or simply needs better explainability before you waste next year's budget scaling a product that users don't actually trust.

**Strongest Reason Against:** This is the slowest and most labor-intensive of the three validation tests. Unlike the Usage Quality Sprint (which is automated) or the Commercial Cleanroom (which is a sales policy change), this requires manual effort from both your team and your customers' adjusters, risking "survey fatigue" or biased sampling.

**Evidence That Would Change My Mind:** If the **Commercial Cleanroom** were to reveal that expansion bookings remain high and buyer enthusiasm persists even without bundle pricing and roadmap promises, it would prove the perceived value is real despite the usage friction. In that case, I would pivot to the **Usage Quality Sprint** to optimize a winning product rather than investigating if the product is broken.

================  OUT-16  ================

---
anonymous_label: OUT-16
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 3cee7dd4947b37c56bea34b98c1502739f26d4281daad352329571551b588be9
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-16

I recommend that you commit to the **Claim File Review**.

**Why:**
Your current "success" is heavily confounded by lagging indicators and artificial incentives. The rise in expansion bookings is tied to temporary pricing bundles (a financial incentive, not a value signal), and the usage spike is driven by managers performing audits rather than adjusters performing work. Furthermore, the "enthusiastic comments" are skewed by sales pitches promising a future roadmap.

The Claim File Review is the only proposal that addresses the "ground truth" of the product's utility. By analyzing whether suggestions were accepted, overridden, or impossible to explain—particularly in the health-liability segment—you move from measuring *activity* (which is currently inflated) to measuring *outcome*. This provides the evidence needed to determine if DraftPath is a scalable asset or a feature that users are simply "performing" for their managers.

**The strongest reason against this recommendation:**
It is the slowest and most labor-intensive of the three validation options. Unlike the Usage Quality Sprint (which relies on existing telemetry) or the Commercial Cleanroom (which relies on sales process changes), a manual file review requires significant time from product ops and cooperation from customers. Given that the board locks the budget in twelve days, this review will not be completed before the deadline; you are choosing to make a budget commitment based on a process that will yield its most critical insights *after* the money is allocated.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" results were to come in immediately showing that renewal intent remains high even without bundle pricing and roadmap promises, it would prove the commercial value is real regardless of the underlying workflow friction. In that case, I would shift the recommendation to "Scale DraftPath Broadly," as the market has already signaled a willingness to pay for the current version of the product.

================  OUT-17  ================

---
anonymous_label: OUT-17
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 3fbd5794b6d75654902722c04dde5d16c8335b3b7157ee6b23b88cab1ae363e7
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-17

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current success is an "entangled" illusion. The financial gains are driven by temporary pricing bundles rather than inherent value, and the usage spike is skewed by managers performing retrospective audits rather than adjusters utilizing the tool in live workflows. Most critically, you have a "black box" problem: adjusters in regulated segments are abandoning the tool because they cannot explain its logic to reviewers.

The Usage Quality Sprint tracks *if* they use it, and the Commercial Cleanroom tracks *if* they will pay for it, but neither explains *why* the product is failing at the point of execution. The Claim File Review is the only option that provides a qualitative audit of whether DraftPath’s output is actually accurate, actionable, or explainable. Before scaling or narrowing the segment, you must determine if the product is providing a "correct" answer that users find confusing or a "wrong" answer that they are simply ignoring.

**Strongest Reason Against:** This is the slowest and most labor-intensive of the three validation tests. Unlike the automated analytics of the Usage Quality Sprint or the contractual data of the Cleanroom, this requires manual effort from adjusters and reviewers, potentially delaying a definitive "go/no-go" signal until after the budget is locked.

**Evidence That Would Change My Mind:** If you discover that "wrong recommendation" tickets are truly near zero and the abandonment in health-liability is purely a training/enablement gap (rather than a product logic failure), I would pivot to the **Usage Quality Sprint**. This would indicate that the core engine is sound and the problem is purely one of user adoption and onboarding.

================  OUT-18  ================

---
anonymous_label: OUT-18
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 44f7623098f8f0ab6738a1040094b16f7d0b5873d3ba4fe495d8f6fc3667fac6
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-18

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the Claim File Review. While your current metrics (expansion bookings, usage percentages) look strong on a dashboard, they are "noisy" and potentially deceptive. You have a classic discrepancy between **perceived value** (Sales/Executive view) and **actual utility** (User view).

The Claim File Review is the only option that solves for the "truth" of the product's efficacy. By auditing actual claim files, you move past vanity usage (managers rerunning samples) and surface-level enthusiasm (bundle-driven renewals). You will discover if DraftPath is actually solving the core problem or if it is simply a "manager's tool" that adjusters find cumbersome or inexplicable. This provides the necessary evidence to decide whether to scale, pivot for health-liability, or rebuild the core logic before the budget is locked.

### The Strongest Reason Against It
The Claim File Review provides **lagging, qualitative data** rather than leading, quantitative data. Unlike the Usage Quality Sprint (which tracks real-time behavior) or the Commercial Cleanroom (which tests immediate price elasticity), a file review is slow and manual. It tells you *what happened* in the past, but it does not instantly prove that fixing a specific friction point will stop the regional carriers from churning or increase the expansion rate in the next quarter.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the regional carriers planning to remove DraftPath are not complaining about *utility* (the "what"), but rather about *value/pricing* (the "how much").

If the account managers report that those carriers love the feature but find the price point unjustifiable regardless of the "bundle" incentive, your problem is a pricing/packaging failure, not a product-market fit failure. In that specific scenario, the Claim File Review is a waste of time because the product works; you simply haven't found the right commercial model.

================  OUT-19  ================

---
anonymous_label: OUT-19
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 4537635f5c459d8526014c49acc4f28f139345d553a0fc2d3da10212d92396d4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-19

**Recommendation:** Run the **Claim File Review**.

**Why:**
Your current success is an illusion created by "the halo effect": strong financial metrics (expansion bookings) are being attributed to product value, but the evidence suggests they are actually driven by pricing incentives (bundle discounts) and sales narratives (roadmap promises).

The critical risk is a "value gap." While usage is up, the data shows it is driven by managers (for training) rather than adjusters (for production). In the high-stakes regulated health-liability segment, the product is failing a fundamental requirement: explainability. If adjusters cannot justify a proposed action to a reviewer, the tool is a liability, not an asset.

The Usage Quality Sprint measures *if* people use it; the Commercial Cleanroom measures *if* people will pay for it. Only the Claim File Review reveals *why* they are abandoning it or overriding it. Before scaling or narrowing your segment, you must determine if DraftPath is solving the core problem or simply creating a new administrative burden that managers are masking during enablement.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation options. Unlike a dashboard (Sprint) or a pricing change (Cleanroom), manual file reviews are qualitative and small-sample. By the time you have a rigorous set of findings, the board may have already locked the budget based on the "strong quarter" momentum, making your findings a post-mortem rather than a pivot.

**Observable evidence that would change my mind:**
If the "regional carriers" who plan to remove DraftPath provide explicit, written feedback stating that their decision is based solely on the lack of a specific integration or a pricing dispute, rather than a failure of the tool’s utility. In that case, the problem is commercial (making the Commercial Cleanroom the priority) rather than a fundamental failure of product-market fit.

================  OUT-20  ================

---
anonymous_label: OUT-20
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 45edc01c9af88a480bdc72221de8ae16c2ee27ccbdb5650ac57893beee899717
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-20

**Recommendation:** Run the Claim File Review.

**Why:**
Your current success is a "mirage" created by lagging indicators and sales incentives. The expansion bookings are driven by temporary pricing bundles (financial engineering) rather than value realization, and the usage spike is driven by managers auditing old files (administrative overhead) rather than adjusters solving claims (core value).

The most critical risk is the "explainability" gap in regulated health-liability and the tendency for adjusters to revert to manual notes. If the product cannot be defended by a user to their internal reviewer, it is not a workflow tool; it is a liability. The Usage Quality Sprint tracks *that* people are using it (which you already know is skewed), and the Commercial Cleanroom tracks *if* people will pay for it (which is a trailing indicator of value). Only the Claim File Review provides "ground truth" evidence of whether DraftPath actually improves the quality of a claim file or simply creates an artifact that is ignored or overridden. You cannot scale a product—or build a roadmap around it—until you know if the "next-action plans" are actually correct or merely plausible.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation options. It requires manual qualitative analysis of files, which provides a smaller sample size than the Usage Quality Sprint and lacks the immediate "hard dollar" validation of the Commercial Cleanroom. In a twelve-day window to lock a budget, it provides the least amount of "board-ready" quantitative data.

**Observable evidence that would change my mind:**
If the "regional carrier" churn (the two accounts already planning to remove DraftPath) is revealed to be caused by a specific, fixable technical bug or a missing integration rather than a failure of the product's core logic/explainability. If the problem is "the plumbing," then scaling or quantitative tracking becomes more urgent than qualitative file review.

================  OUT-21  ================

---
anonymous_label: OUT-21
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 4adfafd12080e6101b48e10b9aaee2eb13752b005da90c1781ae18402ddd4e61
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-21

**Recommendation:** Run the Claim File Review.

**Reasoning:** The current evidence of success is heavily contaminated. Expansion bookings are tied to temporary pricing incentives rather than perceived value, and positive customer sentiment was elicited by sales teams promising future roadmap improvements. Usage metrics are misleading; high activity is driven by managers performing retrospective audits rather than adjusters executing live workflows. Furthermore, the drop in "wrong recommendation" tickets is likely an artifact of users misclassifying bugs as training requests.

The Claim File Review is the only intervention that targets the core risk: a gap between proposed actions and actual utility. Unlike the Usage Quality Sprint, which tracks *if* people click (behavior), or the Commercial Cleanroom, which tracks *if* people pay (financials), this review examines *what* happened inside the claim file (outcome). It will reveal whether the software is actually solving a problem or if adjusters are simply performing "compliance theater" for their managers.

**Strongest Reason Against:** This approach is slow and labor-intensive compared to automated analytics. It provides a snapshot of historical data rather than a real-time signal of market demand, potentially delaying the decision to scale or pivot until after the budget is locked.

**Evidence that would change my mind:** If you discover that the regional carriers removing DraftPath are doing so specifically because of a lack of training/enablement—rather than a failure of the tool's logic or an inability to explain actions to reviewers—I would shift the recommendation to the Usage Quality Sprint. This would indicate the product is valuable but the delivery mechanism is broken, making behavioral tracking and enablement more urgent than a quality audit.

================  OUT-22  ================

---
anonymous_label: OUT-22
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 51ddc90891eb6d1afaa6a639d2bd1dbf1864989856205d20b0ffeda45c8a7a2e
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-22

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is an illusion created by "entangled" data. The expansion bookings are driven by temporary pricing (financial incentive) and roadmap promises (future hope), not current product value. The usage spike is a "false positive" caused by managers auditing the tool rather than adjusters using it to solve claims. Most critically, you have a systemic failure in your most regulated segment (health-liability) where the product fails the "explainability" test—a fatal flaw for B2B workflow software.

The Usage Quality Sprint tracks *how often* people click, but not *why* they abandon. The Commercial Cleanroom tests sales tactics, but doesn't fix the product. Only the Claim File Review provides a "ground truth" audit of whether DraftPath actually solves the core problem (the claim) or is simply being bypassed by the users who matter most. You cannot scale a product that adjusters abandon after two days.

**Strongest Reason Against:** This is the slowest, most labor-intensive option of the three tests. It requires manual effort from adjusters and reviewers who are already busy, and it provides a small sample size compared to the automated data of a Usage Quality Sprint. It risks delaying a "scale" decision by providing nuanced, qualitative friction rather than a clean "yes/no" metric.

**Observable Evidence to Change My Mind:** If the "regional carrier" churn (the two accounts planning to remove DraftPath) was revealed to be based on a specific, missing integration rather than a failure of the core recommendation engine, I would pivot to the Commercial Cleanroom. If the churn is based on a failure of value, the File Review remains the only way to diagnose the cure.

================  OUT-23  ================

---
anonymous_label: OUT-23
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 52078223be1e36abea0e08cafbf103a316beb23ecb4331dfb0d1bbc49cc8067e
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-23

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: The Commercial Cleanroom
You should displace the "scale DraftPath broadly" commitment. Scaling now would be a premature leap based on "halo-tinted" data rather than validated learning.

**Why:**
Your current success signal is contaminated by the **halo effect** (BK-0048-card-001). Because expansion bookings rose and renewals closed early, your executive team is now attributing positive traits—"focused," "commercially disciplined," and "aligned"—to the product team. However, the evidence suggests these results are driven by a temporary bundle price (a financial incentive) and a roadmap pitch (an aspirational promise), not the inherent value of DraftPath.

To establish a "real strategy" (BK-0001-card-001), you need an accurate **diagnosis** of why customers are paying. Currently, your "progress" is measured by execution targets (bookings and renewals) rather than **validated learning** (BK-0007-card-001). The Commercial Cleanroom is the only proposed package that isolates the performance signal from the product value. By removing the price bundle and the roadmap pitch, you test whether the product itself drives expansion intent. If customers stop renewing or expanding without the discount and the "future promise," you have learned that your current growth is a financial artifact, not product-market fit.

### The Strongest Reason Against It
The Commercial Cleanroom creates immediate short-term financial risk. By withholding bundle pricing and roadmap pitches from a matched set of accounts, you may intentionally trigger renewal objections or lose expansion dollars in the current window. In a board-driven environment, this "controlled failure" can be perceived as sabotaging the current momentum for the sake of academic rigor.

### Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** provided empirical evidence that front-line adjusters in non-regulated segments are accepting and acting on DraftPath suggestions without manager oversight. If the "Usage Quality" is fundamentally high—meaning the product solves a decisive problem regardless of how it is priced—the risk shifts from "is this value real?" to "how do we price it?" In that case, the diagnosis changes, and the priority would shift to the Claim File Review to understand the specific mechanics of that value.

================  OUT-24  ================

---
anonymous_label: OUT-24
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 52086538592a48be8bb974748dbd75b14285c1e90736f51d11428088dd756a84
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-24

I recommend that you commit to the **Claim File Review**.

### Reasoning
Your current situation is a classic "false positive" scenario. The executive team sees strong commercial metrics (expansion bookings, shortened cycles), but those are being driven by **sales incentives** (bundle pricing) and **aspirational selling** (roadmap pitches), not necessarily product value.

The most dangerous signal in your data is the behavior of the front-line adjusters: high initial adoption followed by a collapse back to manual notes. This suggests DraftPath is "interesting" but not "useful." When users abandon a tool unless a manager is watching, the product has failed to integrate into the actual workflow; it has merely become a compliance checkbox.

The other options fail to address this core uncertainty:
*   **Scaling Broadly:** This is high-risk. You would be scaling a product that users are already abandoning, potentially baking in churn for next year.
*   **Usage Quality Sprint:** This measures *quantity* of activity (return rates), but your data already shows that usage is being driven by managers rerunning samples for training. More "usage" does not equal more "value."
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. It tells you if people will pay for it without a discount, but it doesn't tell you why the health-liability segment is abandoning it or how to fix the product.
*   **Narrowing to Health-Liability:** This is premature. You don't yet know if the "explainability" issue in health-liability is a systemic product flaw or a specific regulatory hurdle.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move past vanity metrics and support tags to see exactly where the AI fails (overridden vs. rewritten). This tells you if DraftPath is providing a shortcut or creating more work.

### The Trade-off
By choosing the Claim File Review, you are displacing the **Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to scientifically prove whether your current pricing strategy is artificially inflating your growth. You will enter next year without knowing exactly how much of your expansion revenue was "bought" via bundles versus earned via value. You are choosing product-market fit over pricing optimization.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It does not provide the "hard numbers" that a Board of Directors typically prefers during budget locks. While you are digging through files to find the "why," your competitors may be scaling faster, and your Sales team may feel unsupported because you aren't optimizing the commercial engine.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "abandonment" by adjusters was not due to the quality of the suggestions, but due to a lack of internal corporate mandate.

If you found that adjusters *loved* the suggestions but were forbidden from using them by their own internal compliance officers (regardless of whether they could "explain" the action), then DraftPath is a solved technical problem and an unsolved political/commercial problem. In that case, the product isn't broken—the sales and onboarding strategy is.

================  OUT-25  ================

---
anonymous_label: OUT-25
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 5325c57140bcf37ed517e4d45aeb91d4863a0c798c63ec13595969a69726c86a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-25

I recommend the **Claim File Review**.

**Why:**
The current "strong quarter" is a mirage created by lagging indicators and sales incentives. The expansion bookings are driven by temporary pricing bundles, not necessarily product value, and the 39% usage spike is skewed by managers running samples rather than adjusters performing actual work. Most critically, the "wrong recommendation" ticket drop is a reporting artifact (tickets moved to training), and health-liability adjusters are abandoning the tool due to a lack of explainability.

Before scaling or narrowing the product, you must determine if DraftPath is actually solving a problem or if it is simply "theatre" for managers. The Claim File Review is the only option that provides ground-truth data on whether a proposed action was actually useful, rewritten, or ignored in a live claim.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation options. Unlike the Usage Quality Sprint (which relies on existing telemetry) or the Commercial Cleanroom (which is a sales policy change), the File Review requires manual inspection and interviews with users. In a twelve-day window before budget lock, this provides the least "immediate" data and risks being too small a sample size to satisfy an executive team eager to scale.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" results (should they be run in a pilot) showed that renewal rates and expansion intent remained identical even without the roadmap pitch or bundle pricing, it would prove that the market perceives high intrinsic value regardless of the "explainability" or usage gaps. In that case, I would pivot to **scaling DraftPath broadly**, as the current frictions would be seen as minor enablement hurdles rather than fundamental product failures.

================  OUT-26  ================

---
anonymous_label: OUT-26
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 6819242a103281a5c521d054667a7f507942f47bdc3ce67c727848c9695ac1ed
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-26

I recommend that you commit to the **Claim File Review**.

### The Recommendation: Claim File Review
You are currently facing a "false positive" crisis. Your financial metrics (expansion bookings) are being driven by sales incentives (bundle pricing), and your usage metrics are being driven by managers (enablement samples) rather than the actual value-driver: the front-line adjuster.

The Claim File Review is the only proposed action that penetrates the "entangled" evidence to find the ground truth. By auditing whether suggestions were accepted, overridden, or impossible to explain, you move from *proxy metrics* (clicks and tickets) to *outcome metrics* (utility and compliance). This allows you to determine if DraftPath is a product that solves a problem or a feature that Sales is successfully selling. Scaling now would be premature; the Usage Quality Sprint only measures *if* they use it, not *why* they stop; and the Commercial Cleanroom tells you if people will pay for it, but not if the product actually works.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and provides a small sample size compared to the automated data of the Usage Quality Sprint. In a high-pressure environment where the board wants "scale" following a strong quarter, choosing a qualitative audit over a quantitative "sprint" may be perceived by the executive team as a lack of momentum or an overly academic approach to product management.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" feedback in health-liability is an isolated regulatory quirk rather than a systemic logic failure. If the product is fundamentally sound but simply priced incorrectly or pitched too aggressively, the risk shifts from *Product-Market Fit* (Can we build it?) to *Commercial Strategy* (How do we price/sell it?). In that case, validating the willingness to pay without bundles becomes the urgent priority.

================  OUT-27  ================

---
anonymous_label: OUT-27
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 69cadba81b916f88370edb95eec59e05ae53eba9b0bc354d81ff14f26d5b3773
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-27

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current success is a "mirage" created by lagging indicators and sales incentives. Expansion bookings are inflated by temporary bundle pricing, and usage spikes are driven by managers performing retrospective audits rather than adjusters utilizing the tool for live claims. Most critically, you have a "black box" problem: in regulated segments, the tool is abandoned because it lacks explainability. The Claim File Review is the only option that provides a ground-truth audit of whether DraftPath actually solves the core problem (effective claim steering) or if it is merely a novelty that managers like and adjusters ignore.

**Strongest Reason Against:** It is the slowest, most manual process of the three validation tests. Unlike the Usage Quality Sprint (automated tracking) or the Commercial Cleanroom (sales gating), this requires human labor to manually audit files, which may feel too slow given the twelve-day budget deadline.

**Evidence That Would Change My Mind:** If the "wrong recommendation" support tickets—even those rerouted to training—show a statistically significant drop in *actual error rates* (not just ticket volume) across all segments, it would suggest the product is fundamentally sound and the issue is purely one of enablement. In that case, I would shift the recommendation to the **Usage Quality Sprint** to optimize the rollout rather than auditing the core utility.

================  OUT-28  ================

---
anonymous_label: OUT-28
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 760910a27648feb0180ab79cec95bec4aeae1012350e6f4f5d36126b78952e43
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-28

I recommend that you commit to the **Claim File Review**.

### Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) look strong, but your leading indicators (adjuster abandonment, "unexplainable" actions in health-liability, and managers using the tool for auditing rather than production) suggest that DraftPath is providing **perceived value to buyers** but not **realized value for users**.

The "Commercial Cleanroom" is too risky; it tests whether you can sell the product, but you already know you *can* sell it—the problem is whether the product actually works. The "Usage Quality Sprint" is a vanity metric trap; tracking return rates tells you *that* users are leaving, but not *why*.

The **Claim File Review** is the only option that addresses the "black box" problem. In B2B workflow software, especially in regulated insurance, the gap between a "proposed action" and an "executed action" is where churn lives. By auditing the files, you will discover if adjusters are overriding DraftPath because it is wrong, or because they lack the "explainability" required for compliance. This tells you if DraftPath is a product problem (bad logic) or an enablement problem (bad UI/documentation).

### Tradeoffs and Sacrifices
By choosing the Claim File Review, you are explicitly sacrificing **commercial certainty** and **speed of scale**.
*   **Giving up the Cleanroom:** You will not know for certain if the recent revenue spike was purely a result of the bundle pricing and roadmap hype. You are betting that product-market fit is more important than price-point validation right now.
*   **Giving up the Quality Sprint:** You will lack a real-time dashboard of usage. You are trading "big data" (how many people clicked) for "thick data" (why the adjuster ignored this specific suggestion).

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. While you are spending weeks reviewing files, your competitors may be scaling faster, and your sales team may lose momentum because they aren't getting new "roadmap" promises to dangle in front of buyers. If the problem is actually a pricing/packaging issue rather than a utility issue, this review will be a distraction that fails to fix the revenue engine.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "unexplainable" actions in health-liability are actually a legal requirement that cannot be solved by software (i.e., the adjuster *must* write the note manually for compliance). If the product is fundamentally blocked by regulation regardless of how "correct" the AI is, then DraftPath is a niche feature, not a core product. In that case, the only remaining question is how to price it for the non-regulated segments, making the Cleanroom the priority.

================  OUT-29  ================

---
anonymous_label: OUT-29
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 7688aecf78bab417d88beb7cb8d3cb5b7914bedf10934e0150bacc98e579f0e4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-29

I recommend the **Claim File Review**.

### The Recommendation
You should commit to the Claim File Review. Your current growth is "entangled"—driven by temporary pricing incentives and manager-led enablement exercises rather than organic, front-line value. The Usage Quality Sprint measures *that* people are clicking; the Commercial Cleanroom measures *if* people will pay. Neither tells you *why* the product is failing at the point of execution (the "last mile" of adjuster adoption and regulatory explainability).

The Claim File Review is the only option that audits the actual output against the professional standard of a claim file. By identifying where suggestions are overridden or "impossible to explain," you move from tracking proxy metrics (usage) to understanding the product gap. This allows you to fix the core utility before scaling a feature that regional carriers are already signaling they will drop.

### The Strongest Reason Against It
The Claim File Review is a slow, manual, and qualitative process. In a high-pressure environment where the board expects to maintain the current momentum of "expansion bookings," spending your limited resources on a forensic audit rather than a commercial experiment (the Cleanroom) or a scale-up plan may look like a lack of confidence to the executive team. It provides no immediate "top-line" validation and does not stop the potential bleed of regional carriers in the short term.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" feedback in health-liability is a fringe regulatory edge case rather than a systemic flaw. Specifically, if the Claim File Review reveals that 80%+ of suggestions are accepted/implemented in non-regulated segments, but the regional carriers are churning solely due to pricing or procurement shifts rather than product utility, the problem is a sales/packaging issue, not a product-market fit issue. In that case, the Cleanroom becomes the priority to stabilize pricing power.

================  OUT-30  ================

---
anonymous_label: OUT-30
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 76ccb4782d31e5c22d0bbf914ba90ffee1db982446e7683abaef3baebdeb5275
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-30

I recommend that you commit to the **Claim File Review**.

### Reasoning: The "Signal vs. Noise" Problem
Your current data is dangerously entangled. You have a "strong quarter," but it is being driven by two lagging indicators that mask product failure: **financial incentives** (bundle pricing) and **sales narratives** (roadmap promises).

The most alarming evidence is the behavioral pattern of your users:
1. **Managerial Vanity:** Usage is high, but it's coming from managers reviewing *closed* files. This means the tool is being used for auditing or reporting, not for active claim resolution.
2. **The "Novelty Drop":** Adjusters use it for two days and then quit. This is a classic sign of a tool that provides an initial "wow" factor but fails to integrate into the actual cognitive workflow.
3. **The Explainability Gap:** In health-liability, users abandon the tool because they cannot defend its output to reviewers. This is a fundamental product failure in a regulated industry; if an adjuster can't explain the "why," the tool is a liability, not an asset.

The Usage Quality Sprint (analytics) will only tell you *that* people are leaving; it won't tell you *why*. The Commercial Cleanroom (sales test) is too risky and late—you already have regional carriers planning to drop the feature. You cannot solve a value-proposition problem by tweaking the pricing model.

The **Claim File Review** is the only option that treats the product as a workflow tool rather than a sales metric. By seeing exactly where suggestions are overridden or rewritten, you move from "usage percentages" to "utility evidence." You will discover if DraftPath is actually helping resolve claims or if it's just generating "noise" that adjusters have learned to ignore.

### The Trade-offs
By choosing the Claim File Review, you are displacing the **Usage Quality Sprint**. You give up the ability to track real-time behavioral trends across the entire user base. You are trading *breadth* (quantitative dashboards) for *depth* (qualitative truth). If the problem is a simple UI friction point, you might miss it by focusing on file reviews; however, your current evidence suggests the problem is deeper—it's a lack of trust and explainability in the core logic.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and small-sample. It does not provide the "hard numbers" that CEOs and Boards typically crave during budget locks. While you are digging through files to find the truth, your competitors may be scaling "good enough" AI features faster. There is a risk that you spend the next quarter analyzing *why* it's broken while your sales team continues to sell a version of the product that doesn't exist, widening the gap between buyer expectation and user reality.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "regional carrier" churn was an anomaly caused by a specific procurement quirk rather than product dissatisfaction. If you found that the "novelty drop" among adjusters was actually caused by a lack of permissions/access rather than a lack of utility, I would pivot to the **Usage Quality Sprint** to optimize the onboarding funnel. However, based on the "explainability" failure in health-liability, these are unlikely scenarios.

================  OUT-31  ================

---
anonymous_label: OUT-31
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 785e8f4b26684deab6cf6ba67d54e2f89780131887d66ebd71e2dd0755467cbc
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-31

**Recommendation:** Run the Claim File Review.

**Why:** Your current "strong quarter" is built on lagging indicators and skewed data. Expansion bookings are inflated by temporary pricing bundles, and usage spikes are driven by managers performing retrospective audits rather than adjusters improving their daily workflow. The most critical risk is the "invisible" churn from regional carriers and the failure in the health-liability segment due to a lack of explainability.

The Usage Quality Sprint tracks *if* people use the tool, but not *why* they abandon it or if the output is actually correct. The Commercial Cleanroom tests pricing and sales narratives, but does not fix a potentially broken product. Only the Claim File Review provides a high-fidelity look at the "ground truth": whether DraftPath’s suggestions are actually being accepted or manually rewritten. This is the only way to determine if you have a scalable product or a "halo effect" created by aggressive sales bundling and temporary novelty.

**The strongest reason against it:** It is the slowest of the three validation options and provides a small sample size. While Sales and Product Analytics can provide quantitative "signals" quickly, the Claim File Review requires manual effort from adjusters and reviewers, risking a delay in insight that could miss the twelve-day budget window.

**Observable evidence that would change my mind:** If the "regional carrier" churn is revealed to be purely a budgetary decision unrelated to product utility, and if the "enablement requests" in support are proven via a quick audit to be simple UI navigation issues rather than fundamental failures in the AI's logic, I would pivot to the Commercial Cleanroom to optimize pricing and capture the current momentum.

================  OUT-32  ================

---
anonymous_label: OUT-32
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 7ef034ead1096e48fb2303939df000f67c13fd6df25fa67b084d6c85f7717130
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-32

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) are being driven by pricing incentives and sales narratives, not necessarily product value. Your usage metrics (39% increase) are being skewed by managers performing audits, which is a different use case than the intended front-line productivity.

The core risk is that DraftPath is a "demo product"—it looks impressive to executives and managers, but it fails the "last mile" of the adjuster's workflow. The evidence in health-liability (abandonment due to lack of explainability) suggests a fundamental gap between the tool's output and the user's professional requirements.

Here is why I chose the Claim File Review over the other options:

*   **Against Scaling Broadly:** This is reckless. You have evidence of "invisible churn" (regional carriers) and a lack of stickiness among front-line users. Scaling now would likely accelerate churn once the bundle pricing expires.
*   **Against the Usage Quality Sprint:** Analytics can tell you *that* a user stopped using a feature, but it cannot tell you *why*. In a complex B2B workflow, "return rates" are vanity metrics if the users returning are only managers. You don't have a tracking problem; you have a value-proposition problem.
*   **Against the Commercial Cleanroom:** This is too late and too risky. With the budget locking in 12 days, you cannot afford to handicap your sales team's ability to close renewals based on a hypothesis. You need to know if the product works before you test how to price it.
*   **Against Narrowing to Health-Liability:** This is a premature pivot. You don't yet know if the "explainability" issue is a universal flaw in DraftPath or a specific regulatory hurdle for health-liability.

The **Claim File Review** is the only option that provides "ground truth." By seeing exactly where suggestions were overridden or rewritten, you move from guessing based on dashboards to knowing why the product is failing the adjuster. This allows you to fix the core utility before committing next year's budget to a flawed version of the tool.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and qualitative. It provides a "snapshot" rather than a continuous stream of data. While the CEO and Board are currently riding a high from a strong quarter, recommending a manual audit instead of "scaling the winner" may be perceived as a lack of momentum or an overly cautious academic exercise. You risk losing the political capital associated with the "commercially disciplined" label if you cannot translate these qualitative findings into a rapid product iteration.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "invisible churn" from regional carriers was not caused by product failure, but by a specific pricing misalignment (e.g., they love the tool but find the bundle price structure incompatible with their procurement rules). If the product is actually delivering value and the friction is purely commercial, then validating the pricing model becomes the urgent priority.

================  OUT-33  ================

---
anonymous_label: OUT-33
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 7fa8f13444bafc13a3e36bf4e4321f77c544cd7c9045f104c3b48dd8fd80aecb
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-33

I recommend you commit to the **Claim File Review**.

### The Recommendation
You should reject the current narrative of "strong commercial alignment" and instead conduct the Claim File Review. This is the only option that addresses the fundamental risk: **DraftPath may be a "management toy" rather than an "adjuster tool."**

The current growth is likely a mirage created by bundle pricing and manager-level enthusiasm. The usage data is deceptive; high frequency from operations managers (rerunning closed files) does not equal value creation in live claims. The "silent churn" from regional carriers and the abandonment in health-liability suggest a lack of "explainability"—a fatal flaw in regulated insurance.

The Claim File Review is the only method that bypasses the "enablement" noise and the sales-driven feedback loop to see what actually happens inside a live claim file. It will tell you if the product is actually solving the problem or if adjusters are simply performing "compliance theater" when they know a manager is watching.

### The Strongest Reason Against It
**It is slow and qualitative.** Unlike the Usage Quality Sprint or the Commercial Cleanroom, this does not provide a clean, quantitative metric for the board. In a twelve-day window to lock the budget, the CEO may feel this is too "academic" and prefer a high-velocity experiment (Sprint) or a direct revenue test (Cleanroom). By choosing this, you sacrifice the ability to prove immediate financial elasticity or technical usage trends in favor of understanding the actual utility of the output.

### The Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you can prove that the "silent churn" from the two regional carriers is an isolated incident caused by procurement budget cuts rather than product dissatisfaction.

If those removals are purely financial and not functional, the risk shifts from "Product-Market Fit" to "Pricing Strategy." In that case, testing whether the product can sell without bundle discounts (the Cleanroom) becomes the priority to ensure your expansion bookings are sustainable and not just a result of aggressive discounting.

================  OUT-34  ================

---
anonymous_label: OUT-34
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 8481048074ca2f3345225942e23c581ceb8480825b5dd489c8ec9885d4f761fc
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-34

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the **Claim File Review**.

Your current growth is a "false positive" created by commercial incentives (bundle pricing) and managerial vanity (ops managers using the tool for training/oversight), rather than adjuster utility. The most critical risk to your business is not a lack of sales momentum, but a fundamental failure of the product's core value proposition: adjusters are abandoning the tool because it lacks "explainability," particularly in regulated segments.

The Usage Quality Sprint tracks *that* people are using it, and the Commercial Cleanroom tracks *if* people will pay for it, but only the Claim File Review tells you *why* it is failing at the point of execution. Without knowing if suggestions are being overridden or rewritten, you are scaling a "black box" that adjusters don't trust and cannot defend to reviewers.

### The Strongest Reason Against It
The Claim File Review is a slow, qualitative process that provides no immediate "commercial" signal to the board. While Sales and Product Analytics are offering metrics that look like growth or efficiency, a File Review produces a set of "failures" and "overrides." In a high-momentum quarter, recommending a process that explicitly hunts for product deficiencies can be perceived by the executive team as "momentum-killing" or overly academic compared to the immediate revenue signals of a Commercial Cleanroom.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "abandonment" in the health-liability segment is a minority edge case and that the majority of expansion bookings are coming from buyers who are explicitly citing DraftPath's *current* output as the primary reason for their renewal, regardless of whether front-line adjusters are using it. If the "Buyer" (who signs the check) values the oversight capabilities for managers more than the productivity gains for adjusters, the product is actually a "Managerial Audit Tool," not a "Workflow Tool." In that case, the technical flaws in the adjuster's experience are secondary to the commercial value of the oversight.

================  OUT-35  ================

---
anonymous_label: OUT-35
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 863fd95e106b21ec408556d079d018c4a80f1309d6dc130c6975ede9a486c5e8
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-35

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is an illusion created by "entangled" data. You have a classic misalignment between *buyer* signals (executive enthusiasm and bundle-driven renewals) and *user* value (adjusters abandoning the tool or using it only under managerial surveillance).

The Usage Quality Sprint tracks *frequency*, but your data already shows that high frequency is being driven by managers (not the primary users) and "enablement" requests. The Commercial Cleanroom tracks *willingness to pay*, but that is a lagging indicator of whether the product actually solves the workflow problem. Only the Claim File Review addresses the "why" behind the abandonment in health-liability and the manual overrides. To scale a B2B workflow tool, you must prove it reduces cognitive load for the practitioner; currently, your evidence suggests DraftPath is a "manager's toy" rather than an "adjuster's tool."

**Strongest Reason Against:** This is the slowest of the three validation options and provides a small sample size. It does not provide the "hard" financial or aggregate usage numbers that a Board typically prefers during budget locks, potentially making it look like the product team is "over-analyzing" while Sales wants to strike while the iron is hot.

**Observable Evidence that would change my mind:** If the "Commercial Cleanroom" were to reveal that renewal rates and expansion intent remain identical (or higher) even without the bundle pricing and roadmap pitches. That would prove that the perceived value is decoupled from the specific feature's utility, suggesting you have a "sales-led" win rather than a "product-led" one, which would shift the priority toward commercial scaling over workflow validation.

================  OUT-36  ================

---
anonymous_label: OUT-36
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: 93d15e8d663d72ec508c6d7e87621c94faeb0b57e875de1a6db87d875702ec12
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-36

I recommend the **Claim File Review**.

**Why:**
The current success of DraftPath is an "entangled" illusion. Financial gains are driven by temporary pricing bundles rather than intrinsic value, and usage spikes are skewed by managers performing retrospective audits rather than adjusters using the tool for active claims. Most critically, there is a "black box" problem: adjusters in the health-liability segment are abandoning the tool because they cannot explain its logic to reviewers.

The Usage Quality Sprint measures *if* people are returning, but not *why* they are failing. The Commercial Cleanroom measures *willingness to pay*, but doesn't fix the product. Only the Claim File Review provides a granular "ground truth" by revealing exactly where suggestions are overridden or deemed unexplainable. This allows you to determine if DraftPath is a viable product or merely a well-marketed feature before the board locks in a budget for scaling.

**The strongest reason against it:**
It is a manual, labor-intensive process that provides a small sample size. Unlike the Usage Quality Sprint (which uses automated analytics) or the Cleanroom (which tests revenue), this review is slow and may not provide a statistically significant representation of the entire customer base, potentially leading to "anecdotal" product pivots.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel are found to be purely pedagogical (i.e., users understand the logic but don't know which button to click) and the adjuster return rate in non-regulated segments is high and stable, I would pivot to the **Usage Quality Sprint**. This would indicate that the product logic is sound and the problem is merely one of enablement/UI rather than a fundamental failure of the proposed action plans.

================  OUT-37  ================

---
anonymous_label: OUT-37
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: a81aa58d8dbd182e190407ec2e99728657d72d7f80ab72f28a8d7a997b3c58be
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-37

I recommend that you commit to the **Claim File Review**.

### Reasoning and Trade-offs
You are currently facing a "false positive" signal. Your lagging indicators (bookings, renewals) look strong, but your leading indicators (adjuster behavior, health-liability abandonment) are flashing red.

The expansion bookings are heavily contaminated by "bundle pricing" (financial incentive) and the roadmap pitch (future promise), meaning you aren't measuring the value of the *product*, but rather the effectiveness of a *sales promotion*. Meanwhile, your usage spike is driven by managers doing retrospective audits—not adjusters doing real-time work.

Here is why the other options are insufficient or dangerous:
*   **Scaling Broadly:** This is a high-risk gamble. The evidence suggests that while managers like the *idea* of DraftPath, front-line adjusters (the actual users) are abandoning it. Scaling a product with low "stickiness" leads to massive churn in 12 months.
*   **Usage Quality Sprint:** This tracks *if* they use it, but not *why* or *how*. You already know the return rate is low after two days; seeing that trend on a dashboard doesn't tell you how to fix the product.
*   **Commercial Cleanroom:** This tests pricing and sales psychology, but not product-market fit. If the product is fundamentally broken for health-liability or lacks "explainability," no amount of pricing adjustment will save the renewal.
*   **Narrowing to Health-Liability:** This is premature. You have evidence that it's failing in this segment, but you don't yet know if the failure is due to a lack of features or a fundamental flaw in the AI's logic.

The **Claim File Review** is the only option that addresses the "Explainability Gap." In B2B workflow software—especially in regulated insurance—the value is not just the *correct* answer, but the *defensible* answer. If adjusters cannot explain a recommendation to a reviewer, the feature is useless regardless of its accuracy. By inspecting actual files, you move from "vanity metrics" (usage %) to "value metrics" (acceptance vs. override).

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a small sample size compared to the "big data" of a Usage Sprint or the revenue data of a Cleanroom. By choosing this, you are sacrificing **statistical certainty and speed**. You will enter the next fiscal year with a deep understanding of *why* the product fails for some, but you will not have a quantified "lift" in renewal probability to show the board.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "bundle pricing" was not the primary driver of expansion, but rather a secondary convenience. Specifically, if you found that accounts *without* the bundle were still renewing early and specifically citing DraftPath as the reason for their expansion, it would indicate that the product value is higher than the usage data suggests, and your primary risk is pricing strategy rather than product utility.

================  OUT-38  ================

---
anonymous_label: OUT-38
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: aa28486645fdc88dde98aae47b7e720e5cd897058bcc61a1fe98873058e821bc
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-38

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is an illusion created by "entangled" evidence. The financial gains are driven by temporary pricing bundles (incentives), not necessarily value creation. The usage spikes are driven by managers (oversight) rather than adjusters (workflow), and the reduction in support tickets is a reporting artifact (channel shifting). You are facing a classic "false positive" scenario where lagging indicators (bookings) mask leading indicators of failure (adjuster abandonment and inability to explain actions in regulated segments).

The Usage Quality Sprint measures *if* they use it, but not *why* or *how* it fails. The Commercial Cleanroom measures *willingness to pay*, but not the product deficiency causing the churn risk in regional carriers. Only the Claim File Review provides a "ground truth" audit of the actual work product. It will reveal whether DraftPath is providing genuine utility or if it is merely a tool for managers to audit employees, which is a precarious foundation for a B2B scale-up.

**The strongest reason against it:** It is the slowest and most labor-intensive of the three validation options. Unlike a dashboard (Sprint) or a sales experiment (Cleanroom), it requires manual qualitative analysis of files and interviews. In a twelve-day window to lock the budget, this approach provides the least "immediate" data for the board and risks being viewed as too academic compared to hard revenue metrics.

**Observable evidence that would change my mind:** If the "regional carriers" who plan to remove DraftPath are an outlier segment (e.g., they have a specific legacy tech stack) and the "national-broker accounts" show high, sustained daily active usage among *front-line adjusters* (not just managers) without the need for bundle pricing. If the friction is isolated to a small cohort, the Commercial Cleanroom would become the priority to maximize revenue capture.

================  OUT-39  ================

---
anonymous_label: OUT-39
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: b45e9809062a0d0d9bb9885100718edcd2fef72e1a3c416fc33feef6ce5774cf
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-39

**Recommendation: Run the Claim File Review.**

This is the only intervention that isolates whether the product provides actual utility or if current success is a byproduct of financial incentives and social pressure. The expansion bookings are contaminated by bundle pricing, and the positive customer comments are biased by a roadmap pitch that promises future value rather than confirming current value. Furthermore, usage data is misleading; high activity from managers rerunning samples does not equal adjuster adoption, and the drop-off in front-line use suggests a lack of trust or utility. By inspecting actual claim files, you bypass the "enablement" noise and reveal whether the software's output is actually being used to resolve claims or if it is being overridden and ignored.

**The strongest reason against this:**
It is a slow, manual process that provides a small sample size compared to the broad, quantitative data of a usage sprint. It will not provide an immediate "green light" for the board in twelve days and may reveal a failure that contradicts the current optimistic narrative of the executive team, potentially creating internal friction.

**Observable evidence that would change my mind:**
If you discover that the "impossible to explain" issue in health-liability is a simple UI/documentation gap rather than a fundamental failure of the logic, I would shift to narrowing the plan around regulated health-liability workflows. If that specific segment is the only place where the product's failure is visible, solving for the most constrained environment would likely unlock the rest of the market.

================  OUT-40  ================

---
anonymous_label: OUT-40
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: b46f012a8886707a939dce6c66becd7f3dc87fe6a3033ec292322c084a66f4fc
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-40

I recommend the **Commercial Cleanroom**.

### Recommendation: Commercial Cleanroom
You should commit to the Commercial Cleanroom and displace the "scale DraftPath broadly" commitment. Scaling now would be a premature bet on contaminated data.

**Reasoning:**
Your current "strong quarter" is likely a result of the **halo effect** (BK-0048-card-001). The executive team is attributing "commercial discipline" and "focus" to the product team because expansion bookings rose. However, the evidence suggests this performance signal is driving the trait assessment, not the other way around. The growth is entangled with temporary bundle pricing and sales pitches promising a future roadmap, rather than independent evidence of product value.

Furthermore, your current "progress" is based on execution targets (usage spikes and booking numbers) rather than **validated learning** (BK-0007-card-001). The usage data is misleading: ops managers are using the tool for reporting, and adjusters abandon it after two days. To avoid "waste"—which Ries defines as any effort not producing validated learning—you must decouple the financial performance (the halo) from the product's actual value. The Commercial Cleanroom is the only proposed test that removes the confounding variables (bundle pricing and roadmap promises) to see if customers actually value DraftPath.

### The Strongest Reason Against
The Commercial Cleanroom carries the highest immediate political and financial risk. By stopping bundle-price offers and withholding the roadmap pitch, you are intentionally risking a dip in short-term expansion bookings and potentially irritating the sales team during a budget-locking window. This contrasts with the "Usage Quality Sprint" or "Claim File Review," which are lower-friction, internal exercises that do not risk current revenue.

### Observable Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** provided definitive, empirical evidence that front-line adjusters are accepting and acting on DraftPath suggestions without manual rewrites in a significant volume of files. If the "work" is actually happening (validated learning via behavior) and the only problem is a pricing/pitching misalignment, you could skip the Cleanroom and move straight to scaling with a corrected pricing model. However, given that adjusters currently fall back to manual notes and cannot explain the tool to reviewers, this is unlikely.

================  OUT-41  ================

---
anonymous_label: OUT-41
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: bc246f6a92efcc36e59e36965f1a66bd252ee8969f66608bc2ef2571998d354a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-41

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) look strong, but your leading indicators (adjuster abandonment, "impossible to explain" actions in health-liability) are flashing red.

The expansion bookings are contaminated by a bundle price incentive, and the "enthusiastic comments" are likely reactions to the *promise* of a roadmap rather than the *utility* of the current tool. You do not have a growth problem; you have a **value-realization problem**.

Here is why the other options fail:
*   **Scale DraftPath Broadly:** This is the highest-risk move. If front-line adjusters are abandoning the tool after two days, scaling will only accelerate the discovery that the product is "shelfware," leading to a massive churn event next year.
*   **Usage Quality Sprint:** This measures *behavior*, not *value*. High usage by managers rerunning samples is "vanity usage"—it doesn't prove the tool helps adjusters settle claims faster or more accurately.
*   **Commercial Cleanroom:** This tests *pricing and sales positioning*. While useful, it doesn't tell you if the product actually works. If the product is fundamentally flawed for the end-user, no amount of pricing discipline will save it.
*   **Narrow to Health-Liability:** This is a premature pivot based on an anecdote. You know it's failing there, but you don't yet know if the core logic is salvageable or if it's a failure across all segments.

The **Claim File Review** is the only option that provides "ground truth." By inspecting the actual claim files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (acceptance vs. override). It will tell you if the product is actually solving a problem or if managers are simply forcing its use.

### The Trade-off
By choosing the Claim File Review, you are sacrificing **immediate commercial certainty**. You are choosing a slow, manual qualitative process over the fast quantitative data of the Usage Quality Sprint and the revenue-testing of the Commercial Cleanroom. You risk the board feeling that you are "over-analyzing" while bookings are high, and you give up the chance to immediately optimize your pricing strategy for the next fiscal year.

### The Strongest Reason Against This Recommendation
The Claim File Review is a "small N" sample. It provides deep insight but lacks statistical significance. There is a risk that the files you pull are not representative of the broader user base, leading you to make strategic pivots based on a handful of outliers rather than systemic trends.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "bundle price" accounts represent more than 50% of your total expansion revenue and the board's primary concern is immediate cash flow/valuation rather than long-term product-market fit. If the company is in a "growth at all costs" phase to secure a specific valuation milestone, the risk of product failure is secondary to the risk of missing a revenue target.

================  OUT-42  ================

---
anonymous_label: OUT-42
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: c6d2791ae619af5a31e1a2ef27d24ea0f893b0348c2e5ce5a8f889186448fb25
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-42

I recommend that you commit to the **Claim File Review**.

**Why:**
Your current success is an "entangled" illusion. The financial growth is driven by temporary pricing bundles (incentives) and sales pitches about a future roadmap (promises), rather than the current utility of the product. The usage data is misleading: it is inflated by managers running samples for meetings, while front-line adjusters—the actual users—abandon the tool after two days. You have a "black box" problem, particularly in regulated segments where users cannot explain the output to reviewers.

The Usage Quality Sprint only measures *if* they return, not *why* they are failing. The Commercial Cleanroom measures *willingness to pay*, but you already know the value proposition is shaky. The Claim File Review is the only option that provides a qualitative "ground truth" by identifying exactly where DraftPath fails (accepted vs. overridden vs. impossible to explain). This is the necessary diagnostic step before you can either scale or pivot.

**The strongest reason against it:**
It is a slow, manual process that provides a small sample size compared to the automated, broad data of the Usage Quality Sprint. By choosing this, you sacrifice the ability to track real-time behavioral trends across your entire user base in favor of a deep dive into a few files.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel were to suddenly spike in volume and specificity—indicating that users are actively trying to fix the tool to make it work rather than simply abandoning it—I would pivot to the **Usage Quality Sprint** to quantify that friction at scale.

================  OUT-43  ================

---
anonymous_label: OUT-43
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: d5ed96dc60981ee001c956dc0a93a9de9b68947b648878f93b9ec1602117e195
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-43

I recommend the **Commercial Cleanroom**.

### Recommendation
Recommend that the CEO commit to the **Commercial Cleanroom**, displacing the "scale DraftPath broadly" commitment. This means sacrificing the immediate potential for top-line growth from bundle-pricing and roadmap-led sales in exchange for a rigorous test of the product's actual market value.

### Reasoning
The current "surprisingly strong quarter" exhibits a classic **halo effect** (BK-0048-card-001). Because the overall performance signal is positive (expansion bookings up 16%, early renewals), executive leadership has attributed this success to specific product team traits ("focused," "commercially disciplined"). However, the underlying evidence suggests these trait assessments are not independent: expansion dollars are tied to temporary bundle pricing rather than product value, and enthusiastic comments were elicited by a roadmap pitch rather than current utility.

Furthermore, the "progress" currently reported—rising usage and fewer support tickets—is illusory. Usage is driven by managers (not the primary users) for enablement meetings, and support tickets have simply shifted channels. According to the principle of **validated learning** (BK-0007-card-001), progress must be proven by empirical evidence of customer behavior that builds a lasting business. Scaling DraftPath broadly based on halo-tinted data would be "waste," as it executes a plan without validating the core assumption that customers value the feature enough to pay for it without discounts or roadmap promises.

The Commercial Cleanroom is the only proposed package that isolates the performance signal from the product value, testing whether DraftPath drives expansion independently of pricing incentives and sales narratives.

### The Strongest Reason Against
The primary risk is the immediate impact on short-term revenue and sales velocity. By stopping bundle-price offers and withholding the roadmap pitch, you may see a dip in expansion bookings and longer sales cycles in the current quarter. This creates a political risk: if the board is focused on the "strong quarter" momentum, they may view this as a deliberate slowing of growth.

### Observable Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** (or similar internal audit) revealed that front-line adjusters in non-regulated segments were accepting and acting on DraftPath suggestions at a high rate without manager oversight. If the product is providing genuine, independent utility to the end-user regardless of the sales narrative, the risk shifts from "validating value" to "fixing enablement," making the Usage Quality Sprint or scaling more attractive.

================  OUT-44  ================

---
anonymous_label: OUT-44
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: d95ab22c7993f08945b0f6a7e52a9f3810e29c6dccf40203e81d2d0a8318aa36
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-44

### Recommendation: Run the Claim File Review

I recommend you commit to the **Claim File Review**.

#### Reasoning
You are currently facing a classic "false positive" signal. Your lagging indicators (bookings, renewals) look strong, but your leading indicators (user behavior, qualitative feedback) are flashing red.

The expansion bookings are likely a result of **sales engineering** (bundle pricing and roadmap promises) rather than **product value**. The usage spike is a "mirage" caused by managers auditing the tool rather than adjusters using it to do their jobs. Most critically, you have a "black box" problem: in regulated segments, the tool is unusable because it lacks explainability.

Here is why the other options fail:
*   **Scale DraftPath Broadly:** This is reckless. You are seeing signs of "novelty churn" (high initial use, then drop-off). Scaling a leaky bucket only accelerates churn.
*   **Usage Quality Sprint:** This measures *quantity* of behavior, not *quality* of outcome. You already know the return rates are low for adjusters; knowing exactly how low they are doesn't tell you *why* they aren't returning.
*   **Commercial Cleanroom:** This is too late and too risky. With the budget locking in 12 days, you don't have time to run a controlled experiment on renewal cycles. Furthermore, it tests the *price*, not the *product*.
*   **Narrow to Health-Liability:** This is a premature pivot. You know health-liability has an explainability problem, but you don't yet know if the core logic of DraftPath is flawed across all segments or just missing a specific feature (transparency/citations).

The **Claim File Review** is the only option that attacks the root cause: the gap between a "proposed action" and an "executed action." By auditing actual files, you will discover if adjusters are overriding the tool because it's wrong, or simply because they don't trust a suggestion they can't explain. This provides the "ground truth" needed to decide if DraftPath needs a pivot, a feature addition (explainability), or a total rewrite.

#### The Strongest Reason Against It
The Claim File Review is **slow and manually intensive**. Unlike the Usage Quality Sprint, it doesn't provide a real-time dashboard for the board. It relies on a small sample size, which may lead to "anecdotal bias" where the struggles of a few vocal adjusters outweigh the silent success of others. It provides no immediate "commercial" win to justify the budget in the eyes of a Sales-driven executive team.

#### Evidence That Would Change My Mind
I would pivot to the **Usage Quality Sprint** if you discover that the "drop-off" after two days is not due to product failure, but due to a **lack of permissions or technical friction** (e.g., the tool is slow, or adjusters lack the SSO rights to access it daily).

If the data shows that users *want* to return but are blocked by a technical hurdle rather than a value deficit, the problem is an operational one (trackable via event tracking) rather than a strategic one (requiring file review).

================  OUT-45  ================

---
anonymous_label: OUT-45
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: e273afdd3b12653c7ccd0dda3a1619b6f6a9fcb759740f76d0153b14436859bc
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-45

**Recommendation:** Run the **Claim File Review**.

**Why:** The company is currently experiencing a "false positive" signal. Financial growth is being driven by temporary pricing bundles rather than organic value, and usage spikes are skewed by managers performing audits rather than adjusters executing workflows. The most critical risk is a "silent churn" (already evidenced by the regional carriers) caused by a lack of utility or explainability. The Claim File Review is the only option that provides high-fidelity, qualitative data on *why* adjusters are abandoning the tool (e.g., the "impossible to explain" issue in health-liability) and whether the output is actually accurate or simply being overridden. This prevents you from scaling a product that users find unusable or investing in "enablement" for a feature that is fundamentally flawed.

**Strongest Reason Against:** It is the slowest and most manual of the three validation tests. Unlike the Usage Quality Sprint (which uses automated event tracking) or the Commercial Cleanroom (which uses sales data), a file review requires manual effort from both staff and customers, meaning you will have a smaller sample size and slower results as the board deadline approaches.

**Observable Evidence to Change My Mind:** If the "wrong recommendation" tickets in the training channel spike significantly and are accompanied by specific, systemic errors that can be quantified via logs. In that case, the **Usage Quality Sprint** would be superior because it would allow you to track and fix technical accuracy issues in real-time across the entire user base rather than analyzing a small set of static files.

================  OUT-46  ================

---
anonymous_label: OUT-46
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: ea245330882bd16a00411016b66fb7d88aaec7393dc3d2510de8688aff6c084d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-46

I recommend that you commit to the **Commercial Cleanroom**.

### Recommendation: Commit to the Commercial Cleanroom
You should displace the "scale DraftPath broadly" commitment. Scaling now would be a premature bet on success that is currently indistinguishable from noise.

**Reasoning:**
Your current "strong quarter" is highly susceptible to the **halo effect** (BK-0048-card-001). Because expansion bookings and early renewals rose, the executive team has retrospectively attributed "focus" and "commercial discipline" to the product team. However, the evidence suggests these results are driven by a performance signal (the bundle pricing) rather than the product's intrinsic value.

Furthermore, your current "progress" consists of vanity metrics and execution targets—rising usage (39%) and fewer support tickets—which **The Lean Startup** (BK-0007-card-001) warns are unreliable under uncertainty. The usage is driven by managers (not the end-user adjusters) and "enablement" requests, while actual adjuster behavior shows a sharp drop-off after two days.

The Commercial Cleanroom is the only proposal that seeks **validated learning** (BK-0007-card-001). By removing the bundle price and the roadmap pitch, you isolate whether customers are buying the *actual value* of DraftPath or simply responding to a financial incentive and a future promise. This provides the empirical evidence needed to determine if you have a viable product or just a successful short-term sales promotion.

### The Strongest Reason Against This Recommendation
The Commercial Cleanroom creates a direct conflict with the Sales team's short-term incentives. By withholding bundle pricing and roadmap pitches from a matched set of accounts, you risk lowering the expansion bookings for that specific cohort in the immediate term. In a high-pressure environment where the board is locking budgets, the CEO may be reluctant to intentionally "throttle" revenue to gain a diagnostic insight.

### Evidence That Would Change My Mind
I would change this recommendation if the **Claim File Review** were conducted first and showed that front-line adjusters in non-regulated segments were accepting and acting on DraftPath suggestions at a high rate without manager intervention. If the "ground truth" of the claim files proves that the product is solving a decisive challenge for the user, the risk shifts from "is this a real product?" to "how do we price it?", making the Commercial Cleanroom less urgent than scaling or refining the product.

================  OUT-47  ================

---
anonymous_label: OUT-47
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: ee98a9759c8389cc90afcd9cd9e2c2b4e9ac5c23b404c540718a570b54c2ba33
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-47

I recommend you commit to the **Claim File Review**.

### The Recommendation
You must prioritize the Claim File Review over all other options. Your current "strong quarter" is a mirage created by sales incentives (bundle pricing) and superficial usage metrics (manager audits). The core product risk is not a lack of tracking or pricing strategy, but a **fundamental failure of utility and trust** at the adjuster level.

The Claim File Review is the only option that exposes the "truth" of the workflow: whether DraftPath actually solves a problem or is simply being performed for managers. By analyzing accepted vs. overridden vs. unexplainable suggestions, you identify if the product is a productivity tool or a "theatre" tool. Scaling now would be scaling an empty shell; the Usage Quality Sprint only tracks *that* people use it, not *why* they stop; and the Commercial Cleanroom tests pricing on a product that may not have sustainable value.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and qualitative. While the board wants quantitative certainty to lock a budget in twelve days, this process provides "small-n" anecdotal evidence that Sales and Finance may dismiss as non-representative. It does not provide the immediate, clean "win/loss" data that a Commercial Cleanroom or an Analytics Sprint offers, making it the hardest sell to an executive team currently riding a high of expansion bookings.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "unexplainable" actions in health-liability were not a product failure, but a regulatory requirement that your current buyers are already ignoring. If the "overrides" in other segments were actually caused by a lack of user training (enablement) rather than poor logic, the risk shifts from *Product-Market Fit* to *Go-To-Market Execution*. In that specific scenario, the product is "correct," and the primary risk becomes whether customers will pay for it without the bundle discount.

================  OUT-48  ================

---
anonymous_label: OUT-48
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: ef8952e7c1d6da3416e3b428606c23d298c3c798ce3bf9173fd5041bdb65a489
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-48

**Recommendation: Run the Claim File Review.**

The current growth signals are contaminated. Expansion revenue is tied to temporary pricing incentives rather than perceived value, and positive customer feedback was solicited after being promised future roadmap enhancements. Usage data is misleading because it captures managers performing retrospective audits rather than adjusters executing live workflows.

The Claim File Review is the only intervention that targets the "silent" failure points: the high abandonment rate in regulated segments and the tendency for adjusters to revert to manual notes. By inspecting actual files, you move from tracking *that* a button was clicked (which could be noise) to *why* a suggestion was rejected or rewritten. This reveals whether the product is solving a core problem or simply creating an administrative burden that managers are forced to oversee.

The Usage Quality Sprint merely reorganizes existing, potentially flawed data without addressing the root cause of abandonment. The Commercial Cleanroom tests sales tactics and pricing elasticity, but it cannot tell you if the product actually works. Scaling broadly based on current metrics would likely lead to a spike in churn once procurement windows open and the "bundle" incentive expires.

**Strongest reason against this recommendation:**
It is a slow, manual process that provides a small sample size. It will not produce the high-volume statistical confidence of an analytics sprint or the immediate revenue clarity of a cleanroom, potentially leaving you with "anecdotal" evidence while the board demands hard numbers for the budget.

**Observable evidence that would change my mind:**
If you discover that the "manual note" fallback is not due to a lack of trust or explainability, but is instead caused by a specific, easily fixable UI friction point (e.g., a missing "Export to PDF" button), then the Usage Quality Sprint becomes more valuable because the problem is one of accessibility rather than fundamental utility.
